(STTK) Shattuck Labs - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 525m USD | Total Return: 532.3% in 12m
Monoclonal Antibodies, Bispecific Antibodies, Immunotherapies
Total Rating 46
Safety 62
Buy Signal -0.16
Biotechnology
Industry Rotation: -4.2
Industry Rotation: -4.2
Market Cap:
525M
Avg Turnover: 3.09M
Avg Turnover: 3.09M
Risk 3d forecast
Volatility104%
VaR 5th Pctl15.7%
VaR vs Median-9.02%
Reward TTM
Sharpe Ratio2.27
Rel. Str. IBD99.2
Rel. Str. Peer Group95.5
Character TTM
Beta1.497
Beta Downside1.550
Hurst Exponent0.595
Drawdowns 3y
Max DD93.45%
CAGR/Max DD0.34
CAGR/Mean DD0.54
Warnings
Share dilution 120.2% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Leader
Description: STTK Shattuck Labs
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company focused on developing monoclonal and bispecific antibodies for inflammatory and immune-mediated diseases. The firm’s primary pipeline includes SL-325, currently in Phase I trials targeting tumor necrosis factor-like ligand 1A (TL1A), and SL-425, a long-acting version currently in IND-enabling toxicology studies. Additionally, the company maintains preclinical programs for inflammatory bowel disease and an oncology-focused initiative known as TRIM7.
The biotechnology sector often utilizes a high-risk, high-reward business model where valuations are heavily dependent on clinical trial milestones and regulatory approvals rather than immediate revenue. TL1A-targeted therapies represent a competitive area of immunology research, as this pathway is increasingly linked to the regulation of mucosal inflammation and fibrosis.
Investors may find more detailed financial metrics and pipeline updates by exploring ValueRay. Shattuck Labs is headquartered in Austin, Texas, and has been operating since 2016.
- Clinical trial data readouts for SL-325 drive investor confidence and valuation
- R&D expenditure levels impact cash runway and future equity financing needs
- Regulatory approval progress for DR3-based antibodies dictates long-term revenue potential
- Competitive landscape in inflammatory bowel disease market affects projected market share
- Strategic partnerships or licensing agreements provide non-dilutive capital and validation
Piotroski VR‑10 (Strict)
0.0
| Net Income: -49.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA 32.72 > 1.0 |
| NWC/Revenue: 8.95k% < 20% (prev 109.8%; Δ 8.84k% < -1%) |
| CFO/TA -0.40 > 3% & CFO -41.3m > Net Income -49.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.2m) vs 12m ago 120.2% < -2% |
| Gross Margin: -172.6% > 18% (prev 0.57%; Δ -17.3k% > 0.5%) |
| Asset Turnover: 1.12% > 50% (prev 69.72%; Δ -68.61% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z''
-15.00
| A: 0.88 (Total Current Assets 93.8m - Total Current Liabilities 4.25m) / Total Assets 102.1m |
| B: -4.36 (Retained Earnings -445.3m / Total Assets 102.1m) |
| C: -0.57 (EBIT TTM -51.4m / Avg Total Assets 89.6m) |
| D: -70.84 (Book Value of Equity -445.3m / Total Liabilities 6.29m) |
| Altman-Z'' Score: -86.70 = D |
What is the price of STTK shares?
As of May 17, 2026, the stock is trading at USD 6.26 with a total of 265,321 shares traded.
Over the past week, the price has changed by -8.61%, over one month by -12.69%, over three months by +56.50% and over the past year by +532.32%.
Over the past week, the price has changed by -8.61%, over one month by -12.69%, over three months by +56.50% and over the past year by +532.32%.
Is STTK a buy, sell or hold?
Shattuck Labs has received a consensus analysts rating of 3.80.
Therefor, it is recommend to hold STTK.
- StrongBuy: 2
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the STTK price?
| Analysts Target Price | 12.5 | 99.7% |
Shattuck Labs (STTK) - Fundamental Data Overview
as of 12 May 2026
P/S = 525.2616 P/B = 5.4849
Revenue TTM = 1.00m USD
EBIT TTM = -51.4m USD
EBITDA TTM = -47.8m USD
Long Term Debt = 2.42m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = unknown (none)
Debt = 2.42m USD (corrected: LT Debt 2.42m + ST Debt none)
Net Debt = -88.4m USD (from netDebt column, last quarter)
Enterprise Value = 437.3m USD (525.3m + Debt 2.42m - CCE 90.4m)
Interest Coverage Ratio = unknown (Ebit TTM -51.4m / Interest Expense TTM 0.0)
EV/FCF = -10.59x (Enterprise Value 437.3m / FCF TTM -41.3m)
FCF Yield = -9.44% (FCF TTM -41.3m / Enterprise Value 437.3m)
FCF Margin = -4.13k% (FCF TTM -41.3m / Revenue TTM 1.00m)
Net Margin = -4.99k% (Net Income TTM -49.9m / Revenue TTM 1.00m)
Gross Margin = -172.6% ((Revenue TTM 1.00m - Cost of Revenue TTM 2.73m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.28 (Enterprise Value 437.3m / Total Assets 102.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.42m)
Taxrate = 21.0% (US default 21%)
NOPAT = -40.6m (EBIT -51.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.06 (Total Current Assets 93.8m / Total Current Liabilities 4.25m)
Debt / Equity = 0.03 (Debt 2.42m / totalStockholderEquity, last quarter 95.8m)
Debt / EBITDA = 1.85 (negative EBITDA) (Net Debt -88.4m / EBITDA -47.8m)
Debt / FCF = 2.14 (negative FCF - burning cash) (Net Debt -88.4m / FCF TTM -41.3m)
Total Stockholder Equity = 82.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.64% (Net Income -49.9m / Total Assets 102.1m)
RoE = -60.73% (Net Income TTM -49.9m / Total Stockholder Equity 82.1m)
RoCE = -60.83% (EBIT -51.4m / Capital Employed (Equity 82.1m + L.T.Debt 2.42m))
RoIC = -52.39% (negative operating profit) (NOPAT -40.6m / Invested Capital 77.5m)
WACC = 11.20% (E(525.3m)/V(527.7m) * Re(11.25%) + D(2.42m)/V(527.7m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 53.15%
[DCF] Fair Price = unknown (Cash Flow -41.3m)
EPS Correlation: 94.89 | EPS CAGR: 103.4% | SUE: -0.05 | # QB: 0
Revenue Correlation: 37.87 | Revenue CAGR: -14.48% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.14 | Chg30d=-7.11% | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.13 | Chg30d=-4.19% | Revisions=+0% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.46 | Chg30d=+10.42% | Revisions=+20% | GrowthEPS=+33.9% | GrowthRev=-100.0%
EPS next Year (2027-12-31): EPS=-0.51 | Chg30d=-7.14% | Revisions=+20% | GrowthEPS=-10.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +20%